Cargando…

Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study

A simple, sensitive, and specific LC-ESI–MS/MS method for quantification of Montelukast (MO) in human plasma using Montelukast-d(6) (MOD6) as an internal standard (IS) is discussed here. Chromatographic separation was performed on YMC-pack pro C(18), 50 x 4.6 mm, S-3 μm column with an isocratic mobi...

Descripción completa

Detalles Bibliográficos
Autores principales: Challa, Balasekhara Reddy, Awen, Bahlul Z., Chandu, Babu Rao, Khagga, Mukkanti, Kotthapalli, Chandrasekhar Bannoth
Formato: Texto
Lenguaje:English
Publicado: Österreichische Apotheker-Verlagsgesellschaft 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002811/
https://www.ncbi.nlm.nih.gov/pubmed/21179354
http://dx.doi.org/10.3797/scipharm.1002-07
_version_ 1782193788933898240
author Challa, Balasekhara Reddy
Awen, Bahlul Z.
Chandu, Babu Rao
Khagga, Mukkanti
Kotthapalli, Chandrasekhar Bannoth
author_facet Challa, Balasekhara Reddy
Awen, Bahlul Z.
Chandu, Babu Rao
Khagga, Mukkanti
Kotthapalli, Chandrasekhar Bannoth
author_sort Challa, Balasekhara Reddy
collection PubMed
description A simple, sensitive, and specific LC-ESI–MS/MS method for quantification of Montelukast (MO) in human plasma using Montelukast-d(6) (MOD6) as an internal standard (IS) is discussed here. Chromatographic separation was performed on YMC-pack pro C(18), 50 x 4.6 mm, S-3 μm column with an isocratic mobile phase composed of 10mM ammonium formate (pH 4.0):acetonitrile (20:80 v/v), at a flow-rate of 0.8 mL min(−1). MO and MOD6 were detected with proton adducts at m/z 586.2→568.2 and 592.3→574.2 in multiple reaction monitoring (MRM) positive mode respectively. MO and MOD6 were extracted using acetonitrile as precipitating agent. The method was validated over a linear concentration range of 1.0–800.0 ng mL(−1) with correlation coefficient (r(2)) ≥ 0.9996. The intraday precision and accuracy were within 1.91–7.10 and 98.32–99.17. The inter-day precision and accuracy were within 3.42–4.41% and 98.14–99.27% for MO. Both analytes were found to be stable throughout three freeze-thawing cycles, bench top, and autosampler stability studies. This method was utilized successfully for the analysis of plasma samples following oral administration of MO (5 mg) in 31 healthy Indian male human volunteers under fasting conditions.
format Text
id pubmed-3002811
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Österreichische Apotheker-Verlagsgesellschaft
record_format MEDLINE/PubMed
spelling pubmed-30028112010-12-22 Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study Challa, Balasekhara Reddy Awen, Bahlul Z. Chandu, Babu Rao Khagga, Mukkanti Kotthapalli, Chandrasekhar Bannoth Sci Pharm Original Papers A simple, sensitive, and specific LC-ESI–MS/MS method for quantification of Montelukast (MO) in human plasma using Montelukast-d(6) (MOD6) as an internal standard (IS) is discussed here. Chromatographic separation was performed on YMC-pack pro C(18), 50 x 4.6 mm, S-3 μm column with an isocratic mobile phase composed of 10mM ammonium formate (pH 4.0):acetonitrile (20:80 v/v), at a flow-rate of 0.8 mL min(−1). MO and MOD6 were detected with proton adducts at m/z 586.2→568.2 and 592.3→574.2 in multiple reaction monitoring (MRM) positive mode respectively. MO and MOD6 were extracted using acetonitrile as precipitating agent. The method was validated over a linear concentration range of 1.0–800.0 ng mL(−1) with correlation coefficient (r(2)) ≥ 0.9996. The intraday precision and accuracy were within 1.91–7.10 and 98.32–99.17. The inter-day precision and accuracy were within 3.42–4.41% and 98.14–99.27% for MO. Both analytes were found to be stable throughout three freeze-thawing cycles, bench top, and autosampler stability studies. This method was utilized successfully for the analysis of plasma samples following oral administration of MO (5 mg) in 31 healthy Indian male human volunteers under fasting conditions. Österreichische Apotheker-Verlagsgesellschaft 2010 2010-06-04 /pmc/articles/PMC3002811/ /pubmed/21179354 http://dx.doi.org/10.3797/scipharm.1002-07 Text en © Challa et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Challa, Balasekhara Reddy
Awen, Bahlul Z.
Chandu, Babu Rao
Khagga, Mukkanti
Kotthapalli, Chandrasekhar Bannoth
Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study
title Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study
title_full Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study
title_fullStr Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study
title_full_unstemmed Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study
title_short Method Development and Validation of Montelukast in Human Plasma by HPLC Coupled with ESI-MS/MS: Application to a Bioequivalence Study
title_sort method development and validation of montelukast in human plasma by hplc coupled with esi-ms/ms: application to a bioequivalence study
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002811/
https://www.ncbi.nlm.nih.gov/pubmed/21179354
http://dx.doi.org/10.3797/scipharm.1002-07
work_keys_str_mv AT challabalasekharareddy methoddevelopmentandvalidationofmontelukastinhumanplasmabyhplccoupledwithesimsmsapplicationtoabioequivalencestudy
AT awenbahlulz methoddevelopmentandvalidationofmontelukastinhumanplasmabyhplccoupledwithesimsmsapplicationtoabioequivalencestudy
AT chandubaburao methoddevelopmentandvalidationofmontelukastinhumanplasmabyhplccoupledwithesimsmsapplicationtoabioequivalencestudy
AT khaggamukkanti methoddevelopmentandvalidationofmontelukastinhumanplasmabyhplccoupledwithesimsmsapplicationtoabioequivalencestudy
AT kotthapallichandrasekharbannoth methoddevelopmentandvalidationofmontelukastinhumanplasmabyhplccoupledwithesimsmsapplicationtoabioequivalencestudy